Women in Pharma: Manufacturing personal and team success
.png)
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
This month, as we celebrate International Women’s Day on March 8, 2025, and highlighting Women’s History Month throughout the month of March, we sat down with Dr Susanne Lemaine, President at Vetter Development Services USA. Heading the company’s clinical manufacturing facility in Chicago, Illinois, Lemaine discusses her career spanning the globe and the pharmaceutical supply chain, and how to work both towards leadership positions and in a leadership capacity itself.
1. Could you please give a brief overview of yourself and your role at Vetter Development Services?
Vetter is a contract development and manufacturing organisation (CDMO) headquartered in South Germany. Our customers are big and small pharma and biotech companies, and our Chicago offices are located at the Illinois Science and Technology Park in north Chicago. Here, we focus on the clinical field, mostly early clinical phases I and II. I started with Vetter in 2006 in Germany, and was responsible for process implementation. When I applied for the position, I had no clue what process implementation was. It is a bit like technical project management, working with the customer on their process. The customer comes with attributes and parameters, and we implement the manufacturing process on the line in production. We are responsible for processing the drug substance all the way up to visual inspection and packaging, and that’s how I started. At the time, Vetter focused on late clinical phase III trials as phase I and II have special requirements regarding losses, flexibility, timelines, and so on. In 2010, Vetter opened a site dedicated to clinical fill, which was exciting for me as it gave me the opportunity to implement clinical products on a new line. I was chosen, with a group of about 15 German nationals, to move to this site, and I was responsible for manufacturing and process development at the start. In 2015, I took over as lead of the site and I have been here since then on what started as a 2-year contract.
2. How did you originally come to work in pharmaceutical manufacturing, and what challenges did you face throughout your career? How have you overcome these challenges?
I studied technical mathematics and have a PhD in computer simulation and biomedical engineering. I worked for several years in research, working on computer simulations for retinal and cochlear implants with electrical stimulation. I was interested in the medical field, but my education wasn’t necessarily chemistry or pharma, so I was excited to work for Vetter, a CDMO that does not have its own pharma products. The daily challenges I navigate are related to the engineering of equipment and the processes – it was a challenge to begin with as I had never seen a lab other than a computer lab before, and I was responsible for implementing processes and working end-to-end with customers who are themselves very knowledgeable. But Vetter has phenomenal teams in place, so while I was responsible for setting up manufacturing processes, I worked with really good production teams who helped me put together documentation and batch records. That is one of the strengths of Vetter – good teamwork and the company’s high expertise has really helped me settle here.
3. What is the importance of collaboration in your line of work?
Collaboration is, in many ways, very important in our line of business. We are 4500 miles and seven time zones away, but collaboration is critical so that we have the same processes and quality for all of our customers. My team is around 110 people out of the 7000 that work across Vetter globally, so we are a relatively small team. We work very closely together also with the teams in Germany. I enjoy this a lot and think it is very fruitful – combining a lot of experience and expertise with very good planning ahead. I think this is a very good combination to bring forward innovation.
Collaboration with our customers is also very important, and while we use the term ‘customer’, it is really a partnership, especially in early clinical phases. The customer develops a drug product, and we develop a manufacturing process together with them. We have a strategic and open partnership with our customers, so we learn with every new customer, and they profit from our vast experience. In this industry, because it’s so highly regulated, it is important to always network and learn from one another. It’s also valuable to talk with experts to interpret and implement evolving guidance and regulations.
4. How can the pharmaceutical manufacturing sector invest in its employees to support career longevity?
The first thing that comes to mind is continuing education. This does not have to be going back to college – learning can be through collaboration, networking, and working together with experts. Technology changes quickly, and we need to be on top of it. We prioritise advanced education, and support employees in everything remotely related to pharma. Sometimes, you even help develop the careers of employees outside of the company but because they contribute their expertise and time, it adds value internally. I think this commitment also contributes to retention of top talent.
We also have an apprenticeship program for manufacturing employees, which is a good training opportunity and helps us to promote from within. Vetter views an employee from the big picture – we have employees here who have worked in several different departments and are all valuable to the company. In our Chicago offices, 21 out of our 110 employees have been here for more than 10 years, so our retention rate is indicative of our support of employees.
5. What advice do you have for future Women Leaders in Pharma?
I think this is advice that can be said for all industries, but it is to be forward-thinking. The world and its technologies are changing so quickly but in pharma, with all our regulations, developing a new product that doesn’t work can be life-threatening. Development times can be extremely long. In this industry, you need to anticipate what will be the case in, say, 20 years, so you can take a calculated risk. When you’re in a leadership position, you’ll have to make decisions that nobody can be sure is the right one. However, making the decision and working to make that choice happen is critical, which includes leading your team in the direction that you believe is best. Using this as a guiding principle and remembering that we are doing this to make patient lives better will help you find your way.
Have a story to share about diversity, equity, and inclusion in pharma? Contact vivian.xie@informa.com to learn how you can contribute to our Women in Pharma series.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig... -
News Medtech company Beta Bionics targets USD$616 million IPO valuation
California-based insulin delivery device manufacturer Beta Bionics have stated their intentions to target an IPO valuation of USD$616 million in the United States, signalling an optimistic recovery of medtech and biotech public listings.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance